{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:34:14Z","timestamp":1790732054278,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies (mAbs) targeting disialoganglioside 2 (GD2) are an important treatment advance for high\u2010risk neuroblastoma, including in patients with refractory or relapsed disease. Dinutuximab and dinutuximab beta are administered for \u22658\u00a0hours (and up to 10 days for dinutuximab beta), whereas naxitamab is administered over 0.5 to 2\u00a0hours as tolerated. As acute pain is a class effect of anti\u2010GD2 mAbs, effective pain management is crucial to successful treatment. Here, we provide an overview of current pain\u2010management strategies for anti\u2010GD2 mAb infusions, with a focus on strategies suitable for naxitamab infusions, which cause a more rapid onset of often severe pain. We discuss opioid analgesics, ketamine, gabapentin, and other similar agents and nonpharmacologic approaches. Potential future pain\u2010management options are also discussed, in addition to the use of sedatives to reduce the anxiety that may be associated with infusion\u2010related pain. In this expert consensus paper, specific guidance for pain management during naxitamab infusions is provided, as these infusions are administered over 0.5 to 2\u00a0hours and may not need overnight hospitalization based on the physician's assessment, and require rapid\u2010onset analgesia options suitable for potential outpatient administration.<\/jats:p>","DOI":"10.1002\/pbc.30217","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T04:45:10Z","timestamp":1676090710000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pain mitigation and management strategies for anti\u2010GD2 infusions: An expert consensus"],"prefix":"10.1002","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-0058","authenticated-orcid":false,"given":"Karsten","family":"Nysom","sequence":"first","affiliation":[{"name":"Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Gomez","family":"Morad","sequence":"additional","affiliation":[{"name":"Boston Children's Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida Sim\u00e3o","family":"Rafael","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children  Toronto Ontario Canada"},{"name":"Sant Joan de D\u00e9u Barcelona Children's Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Zier","sequence":"additional","affiliation":[{"name":"Children's Respiratory and Critical Care Specialists PA  Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-4782","authenticated-orcid":false,"given":"Araz","family":"Marachelian","sequence":"additional","affiliation":[{"name":"Children's Hospital  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Watt","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center  Dallas\u2010Fort Worth Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-1108","authenticated-orcid":false,"given":"Daniel A.","family":"Morgenstern","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.3392"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.008"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.023"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26192"},{"key":"e_1_2_8_6_1","unstructured":"Unituxin (dinutuximab) [prescribing information].2015. Accessed February 10 2022.https:\/\/unituxin.com\/full\u2010prescribing\u2010information.pdf"},{"key":"e_1_2_8_7_1","unstructured":"European Medicines Agency. Qarziba (previously dinutuximab beta [EUSA] and dinutuximab beta [Apeiron]). Summary of product characteristics. Accessed June 14 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/qarziba\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_8_1","unstructured":"DANYELZA (naxitamab\u2010gqgk) [prescribing information].2020. Accessed February 28 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761171lbl.pdf"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30578-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4005"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1402997"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1130196"},{"key":"e_1_2_8_14_1","article-title":"Immune activation and clinical responses following long\u2010term infusion of anti\u2010GD2 antibody ch14.18\/CHO in combination with interleukin\u20102 in high\u2010risk neuroblastoma patients","volume":"32","author":"Lode HN","year":"2014","journal-title":"Ped Oncol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00469-9"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001369"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25280"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1452"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134255"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000002648"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520903653"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001722"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26967"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216310383739"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jopan.2009.03.005"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2020.08.007"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1043454216659448"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa301"},{"issue":"5","key":"e_1_2_8_29_1","first-page":"456","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anethesiologists","volume":"43","author":"Schwenk ES","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"e_1_2_8_30_1","unstructured":"MoraJ ChamizoA LazaroJJ et\u00a0al. Ketamine\u2010based management of naxitamab (HU3F8) induced pain in the outpatient setting at HSJD. Presented at ANR 2021; Abstract P215."},{"key":"e_1_2_8_31_1","unstructured":"Electronic Medicines Compendium Ketalar summary of product characteristics (SmPC). Accessed March 9 2022.https:\/\/www.medicines.org.uk\/emc\/product\/2231\/smpc#gref"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1043454216680595"},{"key":"e_1_2_8_33_1","article-title":"Outpatient administration of naxitamab in combination with granulocyte\u2010macrophage colony\u2010stimulating factor in patients with refractory and\/or relapsed high\u2010risk neuroblastoma: management of adverse events","author":"Mora J","year":"2022","journal-title":"Cancer Rep"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000000246"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.652552"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2020.09.005"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199504000-00017"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181870a17"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1144"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002109"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199710000-00014"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0000000000000741"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29653","article-title":"Lidocaine for dinutuximab associated pain? A multicenter retrospective observational cohort study","author":"Featherly J","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100462"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1188\/15.ONF.E339-E357"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000075"},{"issue":"2","key":"e_1_2_8_47_1","first-page":"33","article-title":"Multidisciplinary pain management for pediatric patients with acute and chronic pain: a foundational treatment approach when prescribing opioids","volume":"6","author":"Wren AA","year":"2019","journal-title":"Children (Basel)"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000024"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.14.1574"},{"issue":"2","key":"e_1_2_8_50_1","first-page":"S617","article-title":"Implantation of a pioneer naxitamab administration unit in a pediatric oncology European hospital","volume":"65","author":"Llanos C","year":"2018","journal-title":"Pediatr Blood Cancer"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.30217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.30217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.30217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T13:06:23Z","timestamp":1753448783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.30217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/pbc.30217"],"URL":"https:\/\/doi.org\/10.1002\/pbc.30217","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,11]]},"assertion":[{"value":"2022-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e30217"}}